3654 results for «600»

Filter By

3654 results

Precision TAVI - Seering marginal gains

21 May 2026 – From EuroPCR 2026

This session delves into precision techniques in transcatheter aortic valve implantation (TAVI), highlighting novel stepwise implantation methods for self-expanding valves, the effects of internal diameter and valve fracture on gradients post valve-in-valve TAVI, and comparative analyses of implantation-depth variability across large-size TAVI platforms. Additionally, it evaluates...

Risk and prognosis predictors in STEMI

21 May 2026 – From EuroPCR 2026

This session explores key risk and prognostic factors in ST-elevation myocardial infarction (STEMI), encompassing biomarker-based outcome prediction, the influence of low-density lipoprotein cholesterol on myocardial injury, and thrombotic risk in atrial fibrillation patients undergoing PCI. It further examines gender differences in young STEMI patients, the safety...

Left main complications - Part 2

21 May 2026 – From EuroPCR 2026

This session covers intricate complications involving the left main coronary artery (LMCA), highlighting cases of catheter-induced dissections, challenges in chronic total occlusion (CTO) PCI, and rare scenarios such as stent entrapment and complex re-interventions. Emphasis is placed on the critical utility of intravascular ultrasound (IVUS) and...

Novel indications for DCB

21 May 2026 – From EuroPCR 2026

This session reviews emerging clinical applications for drug-coated balloons (DCB) beyond traditional indications. It covers outcomes in venous stenosis, aorto-ostial lesions, and coronary bifurcation disease, comparing DCB strategies with drug-eluting stents and highlighting recent clinical trial findings.

Primary PCI dilemmas: when imaging saves the day

21 May 2026 – From EuroPCR 2026

This session highlights the pivotal role of imaging in resolving dilemmas during primary percutaneous coronary intervention (PCI). It presents complex cases illustrating challenges such as coronary compression, thrombus burden in large vessels, and culprit lesion identification, including the use of high-definition intravascular ultrasound (HD-IVUS) to reclassify...

Optimising TAVI care pathways

21 May 2026 – From EuroPCR 2026

This session examines innovations in TAVI care pathways aimed at improving patient outcomes and healthcare efficiency. Topics include large-scale transatlantic data on day-case TAVI, standardized ECG conduction algorithms reducing hospital stay, nurse-led structured pathways, feasibility of very early discharge, and urgent outpatient TAVI for severe aortic...

CTO PCI in images and case examples: what is new in 2026?

07 Jul 2026

Register for free to this webinar on Monday 31 August at 6:00pm with K. Mashayekhi, M. Ayoub and C. Ungureanu and learn to review the recent evidence on expected outcomes after CTO PCI, and much more!

CTO PCI in images and case examples: what is new in 2026?

Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)

27 Oct 2023

Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)

The greatest advance in the next 40 years would be to remove the need for angioplasty

17 May 2017

Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...

Authors :

Spencer B. King
Spencer B. King

ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI

28 Mar 2026

Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide percutaneous coronary intervention

From PROTECT-AF to CHAMPION-AF: Where do we stand today?

01 Jul 2026

In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.

Jens-Erik-Nielsen-Kudsk

Author

Jens Erik Nielsen-Kudsk
From PROTECT-AF to CHAMPION-AF: Where do we stand today?

COVID-19 vaccines: Burning questions from the community and real-world applicability

13 Jan 2021

View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.

COVID-19 vaccines: Burning questions from the community and real-world applicability

The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation

01 Sep 2025

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Author

Chiara De Biase
The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]

A randomized, placebo-controlled trial of chronic total occlusion PCI in stable angina - ORBITA-CTO trial

03 Apr 2026

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...

John Davies

Author

John Davies
Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Sarosh Khan

Author

Sarosh Khan
ORBITA-CTO: Chronic total occlusion PCI in stable angina
Didn’t find what you were looking for?